Latest From Elizabeth Cairns
Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.
The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.
Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?
A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.
Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings.
The UK big pharma gets a first-in-class approval in breast cancer, but a challenger is emerging.